The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy. Specifically we propose to evaluate a novel second-generation low-molecular-weight prostate specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL, for detection of primary and metastatic prostate cancer. 18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). We propose to evaluate this PET agent for three different prostate cancer clinical scenarios: (1) detection of clinically significant high-grade prostate cancer and initial staging, (2) detection of sites of recurrence in the setting of biochemical recurrence after definitive prostatectomy, and (3) detection of advanced androgen-resistant metastatic prostate cancer.
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
This project was funded by: Radiology RD
The term of this project was: August 2018 to December 2019
The number of subjects scanned during this project was: 36